SLC5A2 and Hypoglycemia: Because hypoglycemia, weight gain, and worsening of glycemic control during long-term usage are of concern in relation to many currently available antihyperglycemic agents [1,2], the development of SGLT2 inhibitors, which are not associated with hypoglycemia or weight gain, is important.